| Literature DB >> 22440913 |
Francisco M Marty1, Michael Boeckh.
Abstract
We summarize the history of the clinical drug development of maribavir for its use as prophylaxis in stem-cell transplant recipients. We highlight key aspects in the design and interpretation of the results of the dose escalation phase II maribavir study that may have contributed to the negative findings on the phase III trials. We discuss key aspects of study design that should be considered in the study of new interventions needed to advance the prevention and treatment of CMV in transplant recipients.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22440913 DOI： 10.1016/j.coviro.2011.10.011
Source DB: PubMed Journal: Curr Opin Virol ISSN： 1879-6257 Impact factor: 7.090